文献速递姑息放疗与转移瘤放疗物理与技术

立体定向放疗在淋巴结寡转移中的系统治疗强化影响评估

Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?
PubMed 文献 · Radiother Oncol · 2020-06-25

该研究回顾性分析了278例淋巴结寡转移患者共327次SBRT治疗,评估其对系统治疗强化、复发模式及预测因素的影响。中位随访15.1个月,1年和2年局部控制率分别为87.2%和76.8%,无治疗强化生存率分别为82.8%和74.5%。结论支持SBRT在多学科管理中对淋巴结寡转移的获益,并建议探索与新型系统治疗的联合。

要点

  • 前列腺原发、小体积、寡复发及BED10≥75 Gy与更高局部控制相关。
  • 1年和2年无治疗强化生存率分别为82.8%和74.5%。
  • SBRT联合免疫/靶向治疗值得研究以减少野外进展风险。

核心结论

  • 在大样本队列中证实SBRT对淋巴结寡转移在多学科管理中的获益。
  • 建议探索SBRT联合新型系统治疗(含免疫和靶向)以降低野外进展风险。

研究设计与样本

  • 回顾性分析278例淋巴结寡转移患者,最多5个寡转移灶,允许同期治疗。
  • 共327次SBRT治疗418个淋巴结,采用容积调强弧形放疗(VMAT)。

主要发现

  • 中位随访15.1个月,1年和2年局部控制率分别为87.2%和76.8%。
  • 前列腺原发肿瘤、小体积、寡复发和BED10≥75 Gy与更高局部控制相关。
  • 1年和2年无治疗强化生存率分别为82.8%和74.5%;系统治疗强化患者中位时间8.43个月,重复SBRT患者中位无治疗强化生存14.6个月。
  • 1年和2年局部区域淋巴结控制率分别为70.9%和57.6%,远处淋巴结控制率分别为82.0%和77.9%。

关键数值与推荐

  • 纳入标准为最多5个寡转移灶。
  • 最常见分割方案为45 Gy分6次,中位BED10为78.75 Gy。
  • BED10≥75 Gy与更高局部控制相关。

临床怎么用

  • SBRT可作为淋巴结寡转移的有效局部消融手段,在多学科管理中应用。
  • 对前列腺原发、小体积、寡复发及BED10≥75 Gy患者可预期更高局部控制。
  • 需关注系统治疗强化风险,重复SBRT患者无治疗强化生存时间较长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Lymph nodes (LN) are common site of oligometastases and stereotactic body radiation therapy (SBRT) represents an effective ablative treatment. Aim of this study was to analyze a large cohort of nodal oligometastases treated with SBRT to identify impact on systemic therapy intensification, pattern of recurrence, and predictive factors. MATERIALS AND METHODS: We included patients with a maximum of 5 oligometastases. Concomitant treatments were allowed. Patients were treated with Volumetric Modulated Arc Therapy (VMAT) and end points were local control of treated metastases (LC), locoregional nodal control (LRNC), distant nodal control (DNC), distant metastases free survival (DMFS), overall survival (OS) and freedom from treatment intensification (FFTI). RESULTS: 418 LN were treated in 278 patients with 327 SBRT treatments. Patients were more commonly affected by colorectal (20.9%) and prostate cancer (17.99%). Most represented schedule was 45 Gy in 6 fractions, with a median BED10 of 78.75 Gy. After median follow-up of 15.1 months, LC at 1 and 2 years were 87.2% and 76.8%, respectively. Prostate primary tumor, small volume, oligorecurrence, and BED10 ≥75 Gy were associated with higher LC. One and 2 years FFTI were 82.8% and 74.5%; in patients reporting intensification of systemic therapy, median time was 8.43 months, while for patients who repeated SBRT, median FFTI was 14.6 months. Rates of LRNC at 1 and 2 years were 70.9% and 57.6%, and DNC were 82.0% and 77.9%. CONCLUSION: With the present analysis, we confirmed on a large cohort the benefit from SBRT on lymph node oligometastases in multidisciplinary management. Combination of SBRT with new systemic therapies, including immunotherapy and targeted therapy, should be investigated to reduce the risk of progression out of the field of irradiation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Franzese C, Badalamenti M, Comito T, et al. Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification? Radiother Oncol. 2020. PMID: 32593644. doi:10.1016/j.radonc.2020.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。